

NB: this is a **summary translation** of the press release original drafted in Japanese for the disclosure in compliance with the TSE regulations. In case of any discrepancy, the Japanese original shall prevail.

9 August 2017

Oncolys BioPharma Inc.

Oncolys Receives Notice of Allowance for EU Patent Expanding OBP-601 IP Protection

Oncolys BioPharma (“Oncolys”) is pleased to announce that it received a notice of allowance for EU patent in relation to a compound of OBP-601, a novel small molecule nucleotide reverse transcriptase inhibitor (NRTI) for HIV infection treatment.

The compound to be patented suggests beneficial effect not only on NRTI (Nucleoside Analogue Reverse Transcriptase Inhibitor)-resistant viruses, but also on those resistant to NNRTI (Non-Nucleoside Analogue Reverse Transcriptase Inhibitor). It also shows considerable effect on viruses resistant to tenofovir DF (Brand Name: Viread) which so far has the biggest share in the anti-HIV drug market worldwide.

The patent was originally applied and registered by Yale University and was licensed exclusively to Oncolys in June 2006. To date, it has been registered in thirteen countries including Japan and United States. Oncolys completed preclinical, CMC, Phase 1a, Phase 1b/2a and Phase 2b clinical studies in the U.S. and other regions for HIV/AIDS therapy, supported by BMS.

The announcement above will not affect Oncolys’ earnings for the fiscal year ending 31 December 2017.

Ends

###

About Oncolys BioPharma Inc.

Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. A novel cancer diagnostic product, TelomeScan®

(OBP-401/1101), is expected to be effective as companion diagnostic tool in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS. For more information, please visit <http://www.oncolys.com/en/>

Oncolys BioPharma Inc.	
Mie Yamazaki Investor Relations & Corporate Communications Tel: +81 (0) 5472 1578 Email: yamazaki@oncolys.com	

TRANSLATION